1
points
1
96
%
1
points
1
96
%
The NCCN-IPI (National Comprehensive Cancer Network International Prognostic Index) is an enhanced prognostic scoring system for diffuse large B-cell lymphoma (DLBCL), the most common aggressive non-Hodgkin lymphoma. Published in 2014 by Zhou and colleagues in Blood, the NCCN-IPI was developed to better stratify risk in the rituximab era, addressing limitations of the original IPI.
Diffuse large B-cell lymphoma accounts for approximately 30-40% of all non-Hodgkin lymphomas and affects roughly 25,000 new patients annually in the United States. While the introduction of rituximab (R-CHOP) in the early 2000s dramatically improved outcomes, DLBCL remains fatal in approximately 30-40% of patients. Accurate prognostic stratification is essential for treatment planning, clinical trial design, and patient counseling.
The original International Prognostic Index (IPI), developed in 1993, used five factors: age over 60, elevated LDH, ECOG performance status 2+, Ann Arbor stage III-IV, and more than one extranodal site. While the IPI remains useful, it has lost some discriminative ability in the rituximab era because overall outcomes have improved and the distribution of patients across risk groups has shifted.
The NCCN-IPI refines the original IPI by providing more granular scoring of age and LDH. Age is scored as 0 (age 40 or below), 1 (41-60), 2 (61-75), or 3 (over 75). LDH ratio is scored as 0 (normal or below), 1 (1-3x upper limit of normal), or 3 (>3x ULN). Additionally, extranodal disease is redefined to include only specific high-risk sites: bone marrow, CNS, liver/GI, and lung.
The NCCN-IPI stratifies patients into four risk groups: low (0-1 points, 96% 5-year OS), low-intermediate (2-3 points, 74% 5-year OS), high-intermediate (4-5 points, 51% 5-year OS), and high (6+ points, 33% 5-year OS). This provides substantially better discrimination between groups compared to the original IPI, particularly in identifying the highest-risk patients who may benefit from alternative or intensified treatment approaches.
The NCCN-IPI has been validated in multiple independent cohorts and is increasingly used in clinical trials as a stratification factor. It is incorporated into the NCCN Clinical Practice Guidelines for B-Cell Lymphomas and is an important tool for discussions about treatment intensity, consolidation strategies, and potential role of autologous stem cell transplantation in high-risk patients.
The NCCN-IPI score is calculated from five factors with refined scoring for age and LDH:
Risk Group: 1=Low (0-1), 2=Low-Int (2-3), 3=High-Int (4-5), 4=High (6+).
A score of 0-1 (Risk Group 1, Low) predicts excellent outcome (~96% 5-year OS). 2-3 (Risk Group 2, Low-Intermediate) predicts ~74% 5-year OS. 4-5 (Risk Group 3, High-Intermediate) predicts ~51% 5-year OS. 6+ (Risk Group 4, High) predicts poor outcome (~33% 5-year OS). Higher risk groups may warrant intensified treatment or clinical trial enrollment.
Inputs
Results
Age 35, normal LDH, stage I-II, no extranodal disease, good performance. Score 0, low risk, 96% 5-year OS.
Inputs
Results
Age 78, very elevated LDH, advanced stage, extranodal disease, poor performance. Score 9, high risk, 33% 5-year OS.
The NCCN-IPI is a refined prognostic scoring system for diffuse large B-cell lymphoma that provides better risk stratification than the original IPI in the rituximab era. It uses enhanced age and LDH scoring and redefined extranodal disease.
NCCN-IPI provides more granular scoring for age (4 levels vs 2) and LDH (3 levels vs 2), and redefines extranodal disease to include only high-risk sites (BM, CNS, liver/GI, lung) rather than any extranodal site.
LDH ratio is the patient's lactate dehydrogenase level divided by the upper limit of normal for the laboratory. An LDH ratio of 1.5 means the LDH is 1.5 times the upper limit of normal.
In the NCCN-IPI, high-risk extranodal sites include bone marrow involvement, central nervous system involvement, liver/gastrointestinal tract involvement, and lung involvement. Other extranodal sites are not counted.
Yes, high-risk patients (score 6+) may be considered for intensified chemotherapy, CNS prophylaxis, or clinical trial enrollment. Low-risk patients typically do well with standard R-CHOP.
R-CHOP is the standard treatment for DLBCL: Rituximab, Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Vincristine (Oncovin), and Prednisone. It is typically given for 6 cycles.
No, the NCCN-IPI was developed specifically for DLBCL. Other lymphoma subtypes (follicular, mantle cell, Burkitt) have their own prognostic scoring systems.
Ann Arbor staging classifies lymphoma extent: Stage I (single lymph node region), Stage II (2+ regions same side of diaphragm), Stage III (regions on both sides of diaphragm), Stage IV (diffuse extranodal involvement).
It was developed using data from 1,650 DLBCL patients treated with R-CHOP at NCCN centers, identifying factors with the strongest independent prognostic significance and optimal cutpoints.
Interim PET-CT (after 2-4 cycles) provides additional prognostic information beyond NCCN-IPI. Combined assessment of NCCN-IPI and interim PET response may further refine risk stratification.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
IPI24 (Lymphoma)
Oncology Risk & Prognosis Calculators
R-IPI (Revised IPI for Lymphoma)
Oncology Risk & Prognosis Calculators
IPSS-R (Myelodysplastic Syndrome)
Oncology Risk & Prognosis Calculators
WPSS (WHO Prognostic Scoring System)
Oncology Risk & Prognosis Calculators
ISS (International Staging System for Myeloma)
Oncology Risk & Prognosis Calculators
R-ISS (Revised ISS for Myeloma)
Oncology Risk & Prognosis Calculators
